These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37672016)

  • 41. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
    Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
    BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
    Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
    Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW
    Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aripiprazole IM depot as an option for the treatment of bipolar disorder.
    Kotzalidis GD; Rapinesi C; Chetoni C; De Filippis S
    Expert Opin Pharmacother; 2021 Aug; 22(11):1407-1416. PubMed ID: 33847183
    [No Abstract]   [Full Text] [Related]  

  • 45. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 48. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study.
    Peters-Strickland T; Baker RA; McQuade RD; Jin N; Eramo A; Perry P; Johnson BR; Duca A; Sanchez R
    NPJ Schizophr; 2015; 1():15039. PubMed ID: 27336044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
    Lauriello J; Claxton A; Du Y; Weiden PJ
    J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32841554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
    de Arce Cordón R; Eding E; Marques-Teixeira J; Milanova V; Rancans E; Schreiner A
    Eur Arch Psychiatry Clin Neurosci; 2012 Mar; 262(2):139-49. PubMed ID: 21809168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
    Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
    Schizophr Res; 2022 Jan; 239():83-91. PubMed ID: 34847501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
    Fleischhacker WW; Sanchez R; Johnson B; Jin N; Forbes RA; McQuade R; Baker RA; Carson W; Kane JM
    Int Clin Psychopharmacol; 2013 Jul; 28(4):171-6. PubMed ID: 23615694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
    J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
    Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
    Kane JM; Osuntokun O; Kryzhanovskaya LA; Xu W; Stauffer VL; Watson SB; Breier A
    J Clin Psychiatry; 2009 Apr; 70(4):572-81. PubMed ID: 19323965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.